16 results about "Skeletal Muscle Tissue" patented technology

The invention discloses an application of ganoderma lucidum spore oil in preparation of a medicine or health food for improving sarcopenia. Ganoderma lucidum spore oil can effectively improve weight loss and muscle hypofunction induced by glucocorticoid, and improve the holding power and exercise tolerance level of the body; meanwhile, the skeletal muscle mass and the muscle fiber cross sectional area can be increased, and the skeletal muscle tissue morphological structure is improved; in addition, the ganoderma lucidum spore oil can improve the oxidation resistance of the body and skeletal muscle and reduce the oxidative stress level, so that the skeletal muscle injury related to aging is relieved on the whole. Therefore, the ganoderma lucidum spore oil has a definite application value in the aspect of improving the skeletal muscle function.

The invention discloses application of hydrogen-rich water in preparation of a drug for treating Duchenne type muscular dystrophy, and particularly relates to the technical field of medicines.The random control experiment is adopted, homologous c57 mice serve as a normal control group, mdx mice are randomly divided into a model group and a hydrogen-rich water group, and the exercise ability is evaluated through a four-limb holding power test and a rotating bar test; detecting mouse creatine kinase by an enzyme-linked immunosorbent assay; carrying out hematoxylin-eosin, NADH-tetrazole reductase and improved Goori three-color dyeing, and carrying out cytochrome C oxidase, succinate dehydrogenase and SDH-COX combined dyeing to observe the pathological change of the skeletal muscle tissue; the invention discloses that the muscle injury condition of a Duchenne type muscular dystrophy model mouse is improved by the hydrogen-rich water through a mitochondrial protection mechanism, and the hydrogen-rich water has a relatively high application prospect and a relatively high economic value.

The invention discloses a method for separating, identifying and proliferating myoblasts of small-tailed han sheep, which comprises the following steps: (1) taking and treating skeletal muscle tissues: selecting healthy small-tailed han sheep, collecting the skeletal muscle tissues under sterile conditions, washing and cutting into pieces to obtain tissue blocks; (2) primary myoblast isolated culture: digesting, filtering and centrifuging the obtained tissue block, and culturing; (3) myoblast purification: purifying the cultured primary myoblasts to obtain purified myoblasts; (4) identifying myoblasts: identifying the obtained purified myoblasts; and (5) proliferation of myoblasts: after identification is completed, carrying out cell proliferation on the purified myoblasts obtained in the step (3) by utilizing a proliferation culture medium containing vitamin E. According to the method provided by the invention, high-purity and high-activity myoblasts can be obtained; vitamin E is utilized, so that the proliferation capacity of myoblasts can be remarkably improved, and the cell differentiation function of the myoblasts is not influenced.

A device includes a first unit for skeletal muscle tissue formation; a second unit for motor neuron culture; a third unit for causing the first and second units to communicate with each other; and a pillar serving as a scaffold for skeletal muscle tissue formation. The first unit includes a first base material and a first culture tank formed in the first base material. The second unit includes a second base material and a second culture tank formed in the second base material. The third unit includes a third base material and an axon channel formed in the third base material, through which a bundle of axons passes. One end of the third unit is connectable to the second unit and cause the axon channel and the second culture tank to communicate with each other. A first opening part is formed to the other end of the third unit.

The application relates to the technical field of animal nutrition and meat quality regulation, and particularly relates to application of vascular endothelial growth factor B (VEGF-B) in increasing intramuscular fat content of pigs. The content of VEGF-B in pig serum and the expression level of VEGF-B in skeletal muscle tissue are significantly positively correlated with the intramuscular fat content of pigs, so that VEGF-B can be used as a biomarker for predicting the intramuscular fat content of pigs; meanwhile, fish oil rich in n-3 polyunsaturated fatty acids can promote the expression level of VEGF-B by activating G protein-coupled receptor 120 (GPR120), then increase the transvascular endothelial transport of fatty acids in blood vessels to skeletal muscle, and finally increase the intramuscular fat content.

The invention relates to the technical field of small nucleic acid drug targeted delivery, and particularly provides an oligonucleotide delivery ligand compound, a conjugate and application thereof. The ligand compound provided by the invention has the effect of improving the delivery capacity of oligonucleotide in extrahepatic tissues such as eye tissues, adipose tissues, nervous tissues and skeletal muscle tissues, and can effectively deliver siRNA drugs to target tissues; it is helpful to alleviate, prevent and / or treat pathological conditions or diseases caused by abnormal expression of specific genes in tissue cells.

The invention discloses a lactobacillus rhamnosus CQFP202457 and application of the lactobacillus rhamnosus CQFP202457 and ellagic acid in relieving exercise fatigue, and belongs to the technical field of microorganisms. The preservation number of the lactobacillus rhamnosus CQFP202457 is CGMCC (China General Microbiological Culture Collection Center) No. 29784. The composition provided by the invention contains ellagic acid and lactobacillus rhamnosus CQFP202457, and can significantly prolong the exercise exhaustion time, reduce the content of fatigue-related metabolites in serum, improve the total antioxidant ability of serum, liver and skeletal muscle and the antioxidant enzyme gene expression level, and improve the exercise-induced liver and skeletal muscle tissue damage. The strain and the composition thereof provided by the invention can be used as exercise synbiotics for preparing products for relieving exercise-induced fatigue, improving exercise performance, reducing exercise-induced oxidative stress or relieving exercise-induced muscle injury.

In one embodiment, the invention provides a dual-cassette gene vehicle comprising cassettes for expression of both a mini-dystrophin gene and NF-κB / p65-shRNA gene in cardiac muscle tissue and skeletal muscle tissue, which is an adeno-associated viral (AAV) vector, wherein the mini-dystrophin gene is operably linked to a construct comprising a muscle-specific first promoter and a modified Mcken (MCK) enhancer and wherein the NF-κB / p65-shRNA gene is under the control of a second promoter. Also are provided pharmaceutical compositions comprising such gene vehicles and a method for ameliorating Duchenne muscular dystrophy (DMD) employing such gene delivery vehicles and pharmaceutical compositions.

The invention relates to novel application of ergothioneine, in particular to application of ergothioneine in preparation of a preparation for assisting in relieving exercise-induced fatigue. It is found that ergothioneine has a very remarkable effect on assisting in relieving exercise-induced fatigue, and particularly, ergothioneine can enhance the exercise tolerance of the body, improve the removal efficiency of metabolic waste generated by exercise, relieve skeletal muscle tissue damage, improve oxidative stress damage of the body and improve the inflammatory state of the body. The ergothioneine is used for preparing products with related effects and has an application prospect.

Provided are a modified nucleoside, a use and method for using the nucleoside to prepare an RNAi preparation for extrahepatic delivery, and an RNAi preparation for extrahepatic delivery obtained thereby. The RNAi preparation can effectively deliver RNAi to extrahepatic tissue, such as muscle tissue, like skeletal muscle tissue and myocardial tissue, and adipose tissue.

This invention provides a co-culture device and a method for producing co-cultured tissue that can reproduce the junctional state between motor neurons and skeletal muscle tissue in vivo, and that allows the neuro-skeletal muscle co-cultured tissue obtained by co-culture to be easily used in other experiments. [Solution] The co-culture device (1) for co-culturing motor neurons and skeletal muscle tissue comprises a pair of anchor members (2a) each supporting skeletal muscle tissue 10a, a pair of well members (2b) attached to the upper part of the pair of anchor members (2a) and in which motor neurons (10b) are seeded, and a base member (3) that supports the pair of anchor members (2a) from below. Each well member (2b) has multiple through holes (2b1a) formed on the inner bottom surface that penetrate to the bottom surface, and each anchor member (2a) has a pillar portion (2a2) that protrudes upward and supports skeletal muscle tissue (10a), and the pair of anchor members (2a) can be detachably attached to the base member (3).

The invention provides a transferrin receptor (TfR1) antibody for conjugation to therapeutic payloads. The TfR1 antibodies may be used for delivering the therapeutic payloads, for instance oligonucleotide-based agents, to CNS tissues, skeletal muscle tissues, or heart tissues in vivo.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an Androgen Receptor (AR) gene. The AR RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an AR gene. Pharmaceutical compositions that include one or more AR RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described AR RNAi agents to central nervous system (CNS) tissue and / or skeletal muscle tissue, in vivo, provides for inhibition of AR gene expression and a reduction in AR activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including spinal and bulbar muscular atrophy (SBMA).

The application describes methods for producing artificial skeletal muscle tissue from pluripotent stem cells. A method for producing skeletal myoblasts, skeletal myotubes and satellite cells from pluripotent stem cells is also disclosed. During the described methods, there is directed differentiation and maturation of the pluripotent stem cells into skeletal myotubes and satellite cells. The application also describes artificial skeletal muscle tissue which has multinuclear skeletal muscle fibres with satellite cells. Furthermore, the invention relates to mesodermally differentiated skeletal myoblast precursor cells, myogenically specified skeletal myoblast precursor cells, skeletal myoblast cells, satellite cells and skeletal myotubes, which can be produced by means of the disclosed methods. The application also describes the use of skeletal muscle tissue or the disclosed cells in drug testing or in medicine. Lastly, the application relates to in vitro methods in which the skeletal muscle tissue or the disclosed cells are used.

The application discloses a biological hybrid driver with a high-efficiency gradient connection structure and a working method, the driver is composed of skeletal muscle tissue, a gradient connection structure and a mechanical framework, the skeletal muscle tissue is connected with the gradient connection structure through proliferation and differentiation of myoblasts; the mechanical framework comprises a support and a crossbeam; the support is arranged on the two sides of the crossbeam respectively; the gradient connection structure comprises parallel fiber bundles, sinusoidal fiber bundles and cross fiber bundles; the parallel fiber bundles are located at the middle part of the gradient connection structure, the sinusoidal fiber bundles are arranged on the two sides of the parallel fiber bundles, and the cross fiber bundles are arranged on one side of the sinusoidal fiber bundles and connected with the support, so that the problem of limited driving performance of the biological hybrid robot is solved, the high-efficiency connection structure can store and release energy, thereby guaranteeing efficient mechanical transmission between the living body and the mechanical body and improving the motion performance of the biological hybrid robot system.

The invention discloses an application of phloretin in preparation of a drug for improving muscular atrophy. The invention proposes and verifies that phloretin can effectively improve muscular atrophy, especially muscular atrophy caused by tumor cachexia for the first time; experimental data show that by applying the phloretin for treatment, weight loss of a mouse with tumor cachexia can be remarkably restrained, meanwhile, the weight of skeletal muscle tissue of the mouse is increased, the cross sectional area of skeletal muscle is increased, and a medicine selection with great application potential is provided for clinical treatment.